Management of BsAb Toxicities by Community Oncologists Across Therapeutic Indications

Video content above is prompted by the following:

Review the recommendations on identifying, evaluating, and managing neurological toxicities.

• Workup and evaluation
• Grading of neurological toxicity
• Management of neurological toxicities
• Are there any other toxicities that are important to mention?

Please discuss the differences/similarities of bispecific antibody (BsAb) adverse event management in non-Hodgkin lymphoma vs other therapeutic indications (eg, multiple myeloma, non–small cell lung cancer).

• Is there a greater incidence of cytokine release syndrome or neurological toxicity in one disease state vs the other?
• Please address differences in BsAb protocols in different disease states.